MARKET

ARCT

ARCT

Arcturus Therape
NASDAQ
6.83
+0.24
+3.64%
After Hours: 6.75 -0.08 -1.17% 19:56 12/04 EST
OPEN
6.54
PREV CLOSE
6.59
HIGH
6.85
LOW
6.47
VOLUME
666.38K
TURNOVER
--
52 WEEK HIGH
24.17
52 WEEK LOW
5.85
MARKET CAP
194.06M
P/E (TTM)
-2.7765
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ARCT last week (1124-1128)?
Weekly Report · 3d ago
Arcturus Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Reuters · 11/24 21:01
Weekly Report: what happened at ARCT last week (1117-1121)?
Weekly Report · 11/24 10:28
Weekly Report: what happened at ARCT last week (1110-1114)?
Weekly Report · 11/17 10:29
Arcturus Therapeutics Price Target Cut to $9.00/Share From $12.00 by Citigroup
Dow Jones · 11/13 20:15
Arcturus Therapeutics Is Maintained at Neutral by Citigroup
Dow Jones · 11/13 20:15
Citigroup Maintains Neutral on Arcturus Therapeutics, Lowers Price Target to $9
Benzinga · 11/13 20:05
Arcturus Therapeutics price target lowered to $9 from $12 at Citi
TipRanks · 11/13 11:40
More
About ARCT
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.

Webull offers Arcturus Therapeutics Holdings Inc stock information, including NASDAQ: ARCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARCT stock methods without spending real money on the virtual paper trading platform.